A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2013
At a glance
- Drugs Genz 644282 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Oct 2012 Planned end date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 03 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.